title: Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia.
authors.forename: E
authors.initials: E
authors.lastname: Harris
authors.forename: J
authors.initials: J
authors.lastname: Behrens
authors.forename: D
authors.initials: D
authors.lastname: Samson
authors.forename: A
authors.initials: A
authors.lastname: Rahemtulla
authors.forename: N H
authors.initials: NH
authors.lastname: Russell
authors.forename: J L
authors.initials: JL
authors.lastname: Byrne
mesh_terms: D058186:Acute Kidney Injury / Q000150:complications*; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D005260:Female; D006801:Humans; D006947:Hyperkalemia / Q000139:chemically induced*; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications*; D013792:Thalidomide / Q000009:adverse effects*
chemical_list: D020533:Angiogenesis Inhibitors; D013792:Thalidomide